New York, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA ...

Please provide your email address to receive an email when new articles are posted on . Patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis share comparable disease burden ...

PRNewswire/ -- (NYSE: JNJ) today announced that TREMFYA® (guselkumab) met the primary and major secondary endpoints ...

November 10, 2011 (Chicago, Illinois) — Adalimumab significantly improved signs and symptoms of axial spondyloarthritis in patients without classic radiographic criteria, according to results of the ...

Johnson & Johnson (JNJ) said Friday Tremfya met the primary and major secondary endpoints in a phase 4 study, showing significant improvements in axial symptoms and a reduction in MRI-confirmed ...

Johnson & Johnson announced that TREMFYA® (guselkumab) met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in ...

Ankylosing Spondylitis (AS) is the leading chronic progressive inflammatory rheumatic disease that involves the sacroiliac joints (SIJs) and the spinal column but is often difficult to recognize in ...

Background A 32-year-old white man presented with features of inflammatory back pain, including awakening at night and morning stiffness. He had acute back pain 4 years earlier as a result of a ...